Topical antifungal drugs for the treatment of onychomycosis: An overview of current strategies for monotherapy and combination therapy

Journal of the European Academy of Dermatology and Venereology

Volumn 19, Issue 1, 2005, Pages 21-29

  Baran, R ^a   Kaoukhov, A ^b  

^a NAIL DISEASE CENTRE   (France)

^b Galderma R and D   (France)

Author keywords

Antifungal nail lacquers; Combination therapy; Onychomycosis

Indexed keywords

AMOROLFINE; ANTIFUNGAL AGENT; BIFONAZOLE; CICLOPIROX; ERGOSTEROL; FLUCONAZOLE; GRISEOFULVIN; ISOCONAZOLE; ITRACONAZOLE; MICONAZOLE; TERBINAFINE; TIOCONAZOLE; UREA;

ANTIFUNGAL ACTIVITY; CLINICAL STUDY; CLINICAL TRIAL; COST BENEFIT ANALYSIS; DATA ANALYSIS; DRUG DELIVERY SYSTEM; DRUG DOSE REGIMEN; DRUG EFFICACY; DRUG FORMULATION; DRUG PENETRATION; DRUG TISSUE LEVEL; ECONOMIC EVALUATION; EPIDERMOPHYTON; ERYTHEMA; GASTROINTESTINAL DISEASE; HEADACHE; HEALTH CARE COST; HEALTH CARE DELIVERY; HUMAN; META ANALYSIS; MICROSPORUM; MONOTHERAPY; NAIL BED; ONYCHOMYCOSIS; PATIENT CARE; PRIORITY JOURNAL; PRURITUS; REVIEW; RISK ASSESSMENT; SKIN BURNING SENSATION; SKIN EDEMA; TREATMENT OUTCOME; TREATMENT PLANNING; TRICHOPHYTON;

ADMINISTRATION, ORAL; ADMINISTRATION, TOPICAL; ANTIFUNGAL AGENTS; CLINICAL TRIALS; DRUG THERAPY, COMBINATION; HUMANS; MORPHOLINES; ONYCHOMYCOSIS; PYRIDONES; RISK FACTORS;

EID: 13944258182     PISSN: 09269959     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1468-3083.2004.00988.x     Document Type: Review

References (58)

1. Zaias N. Onychomycosis. Arch Dermatol 1972; 105: 263-274.
2. Elewski BE. Onychomycosis: pathogenesis, diagnosis, and management. Clin Microbiol Rev 1998; 11: 415-429.
3. Roberts DT. Onychomycosis: current treatment and future challenges. Br J Dermatol 1999; 141 (Suppl 56): 1-4.
4. Roberts DT. Prevalence of dermatophyte onychomycosis in the United Kingdom: results of an omnibus survey. Br J Dermatol 1992; 126 (Suppl. 39): 23-27.
5. Meinhof W. Tinea unguium. In: Korting G, ed. Dermatologic in Klinik and Praxis. Thieme, Stuttgart, Germany, 1980: 19.4-19.5.
6. Andre J, Achten G. Onychomycosis. Int J Dermatol 1987; 26: 481-490.
7. Gupta AK, Jain HC, Lynde CW, Watteel GN, Summerbell RC. Prevalence and epidemiology of unsuspected onychomycosis in patients visiting dermatologists' offices in Ontario, Canada - a multicenter survey of 2001 patients. Int J Dermatol 1997; 36: 783-787.
8. Gupta AK, Lynde CW, Jain HC, Sissald RG, Elewski BE, Daniel CR III, Watteel GN, Summerbell RC. A higher prevalence of onychomycosis in psoriatics compared with non-psoriatics: a multicentre study. Br J Dermatol 1997; 136: 786-789.
9. Gupta AK et al. Prevalence and epidemiology of toenail onychomycosis in diabetic subjects: a multicentre survey. Br J Dermatol 1998; 139: 665-671.
10. Cohn MS. Superficial fungal infections. Topical and oral treatment of common types. Postgrad Med 1992; 91: 239-252.
11. Ravnborg L, Baastrup N, Svejgaard E. Onychomycosis in HIV-infected patients. Acta Derm Venereol 1998; 78: 151-152.
12. Baran R, Hay RJ, Tosti A, Haneke E. A new classification of onychomycosis. Br J Dermatol 1998; 139: 567-571.
13. Roseeuw D. Achilles foot screening project: preliminary results of patients screened by dermatologists. J Eur Acad Dermatol Venereol 1999; 12 (Suppl 1): S6-S9.
14. Drake LA, Scher RK, Smith EB, Faich GA, Smith SL, Hong JJ, Stiller MJ. Effect of onychomycosis on quality of life. J Am Acad Dermatol 1998; 38: 702-704.
15. Gupta AK, Einarson TR, Summerbell RC, Shear NH. An overview of topical antifungal therapy in dermatomycoses: a North American perspective. Drugs 1998; 55: 645-674.
16. Gupta AK, Scher RK, De Donker P. Current management of onychomycosis: an overview. Dermatol Clinics 1997; 15: 121-135.
17. Bohn M, Kraemer KT. Dermatopharmacology of ciclopirox nail lacquer topical solution 8% in the treatment of onychomycosis. J Am Acad Dermatol 2000; 43: S57-S59.
18. Polak A, Dixon. Antifungal activity of amorolfine in vitro and in vivo. In: Fromtling R, ed. Recent Trends in the Discovery, Development and Evaluation of Antifungal Agents. JR Prous Science Publications, Barcelona, 1987: 555-573.
19. Marty J-PL. Amorolfine nail lacquer: a novel formulation. J Eur Acad Dermatol Venereol 1995; 4 (Suppl 1): S17-S21.
20. Pittrof F, Gerhards J, Erni W, Klecak G. Loceryl nail lacquer - realization of a new galenical approach to onychomycosis therapy. Clin Exp Dermatol 1992; 1: 26-28.
21. Gupta AK, Baran R. Ciclopirox nail lacquer solution 8% in the 21st century. J Am Acad Dermatol 2000; 43: S96-S102.
22. Murdan S. Drug delivery to the nail following topical application. Int J Pharm 2002; 236: 1-26.
23. Polak A. Kinetics of amorolfine in human nails. Mycoses 1993; 36: 101-103.
24. Franz TJ. Absorption of amorolfine through human nail. Dermatology 1992; 184 (Suppl 1): 18-20.
25. Mensing H, Polak-Wyss A, Splanemann V. Determination of the subungual antifungal activity of amorolfine after 1 month's treatment in patients with onychomycosis: comparison of two nail lacquer formulations. Clin Exp Dermatol 1992; 17 (Suppl. 1): 29-32.
26. Epstein E. How often does oral treatment of toenail onychomycosis produce a disease-free nail? An analysis of published data. Arch Dermatol 1998; 134: 1551-1554.
27. Hay RJ, Mackie RM, Clayton YM. Tioconazole nail solution - an open study of its efficacy in onychomycosis. Clin Exp Dermatol 1985; 10: 111-115.
28. Rollman O. Treatment of onychomycosis by partial nail avulsion and topical miconazole. Dermatologica 1982; 165: 54-61.
29. Nolting S. Non-traumatic removal of the nail and simultaneous treatment of onychomycosis. Dermatologica 1984; 169: 117-120.
30. Hay R, Roberts D, Doherty V. The topical treatment of onychomycosis using a new combined urea/imidazole preparation. Clin Exp Dermatol 1988; 13: 164-167.
31. Hardjoko FS et al. Treatment of onychomycosis with a bifonazole-urea combination. Mycoses 1990; 33: 167-171.
32. Torres-Rodriguez JM, Madrenys N, Nicolas MC. Non-traumatic topical treatment of onychomycosis with urea associated with bifonazole. Mycoses 1991; 34: 499-504.
33. Bonifaz A, Guzman A, Garcia C, Sosa J, Saul A. Efficacy and safety of bifonazole urea in the two-phase treatment of onychomycosis. Int J Dermatol 1995; 34: 500-503.
34. Gupta A. Ciclopirox: an overview. Int J Dermatol 2001; 40: 305-310.
35. Gupta AK, Joseph WS. Ciclopirox 8% nail lacquer in the treatment of onychomycosis of the toenails in the United States. J Am Podiatric Med Assoc 2000; 90: 495-501.
36. Gupta AK, Fleckman P, Baran R. Ciclopirox nail lacquer topical solution 8% in the treatment of toenail onychomycosis. J AM Acad Dermatol 2000; 43: S70-S80.
37. Lauharanta J. Comparative efficacy and safety of amorolfine nail lacquer 2% versus 5% once weekly. Clin Exp Dermatol 1992; 17 (Suppl 1): 41-43.
38. Reinel D, Clarke C. Comparative efficacy and safety of amorolfine nail lacquer 5% in onychomycosis, once-weekly versus twice-weekly. Clin Exp Dermatol 1992; 17 (Suppl 1): 44-49.
39. Zaug M, Bergstraesser M. Amorolfine in the treatment of onychomycoses and dermatomycoses (an overview). Clin Exp Dermatol 1992; 17 (Suppl 1): 61-70.
40. Einarson T. Pharmacoeconomic applications of meta-analysis for single groups using antifungal onychomycosis lacquers as an example. Clin Ther 1997; 19: 559-569.
41. Polak A. The past, present and future of antimycotic combination therapy. Mycoses 1999; 42: 355-370.
42. Evans E. The rationale for combination therapy. Br J Dermatol 2001; 145 (Suppl 60): 9-13.
43. Hay RJ, Clayton YM, Moore MK. A comparison of tioconazole 28% nail solution versus base as an adjunct to oral griseofulvin in patients with onychomycosis. Clin Exp Dermatol 1987; 12: 175-177.
44. Arenas R, Fernandez G, Dominguez L. Onychomycosis treated with itraconazole or griseofulvin alone with and without a topical antimycotic or keratolytic agent. Int J Dermatol 1991; 30: 586-589.
45. Nolting S. Open studies of ciclopirox nail lacquer in onychomycosis: a review. In: Shuster S, ed. Hydroxy-pyridones as Antifungal Agents with Special Emphasis on Onychomycosis. Springer-Verlag, Berlin, 1999: 75-80.
46. Polak A. Combination of amorolfine with various antifungal drugs in dermatophytosis. Mycoses 1993; 36: 43-49.
47. Zaug M. Amorolfine nail lacquer: clinical experience in onychomycosis. J Eur Acad Dermatol Venereol 1995: S23-S30.
48. Baran R, Feuilhade M, Combernale P, Datry A, Goettman S, Pietrini P, Viguie C, Badillet G, Larnier C, Czernielewski J. A randomized trial of amorolfine 5% solution nail lacquer combined with oral terbinafine compared with terbinafine alone in the treatment of dermatophytic toenail onychomycoses affecting the matrix region. Br J Dermatol 2000; 142: 1177-1183.
49. Lecha M. Amorolfine and itraconazole combination for severe toenail onychomycosis; results of an open randomized trial in Spain. Br J Dermatol 2001; 145 (Suppl 60): 21-26.
50. Maleszka R, Ratajczak V, Turek-Krasinska K, Glabowska D. The use of amorolfine in the treatment of dermatophyte onychomycosis. Prz Dermatol 2002; 89: 493-496.
51. Adaskevich U, Evseenko I. Itraconazole in combined treatment of patients with onychomycosis (Abstract PP1-1). J Eur Acad Dermatol Venereol 2003; 17 (Suppl 1): 47.
52. Sergeev A, Sergeev Y. Combined treatment of onychomycosis with fluconazole and amorolfine nail lacquer. In: 4th Congress of the European Confederation of Medical Mycology. Glasgow, 1998.
53. Sergeev Y, Sergeev A. Pulsed combination therapy: the new option for onychomycosis. Mycoses 2001; 44 (Suppl 1): 68-69.
54. Baran E, Bochenski J. Combined approach to onychomycosis management (Abstract SP5-1). J Eur Acad Dermatol Venereol 2003; 17 (Suppl 1): 40.
55. Lecha M, Alsina M, Torres-Rodriguez JM, Ruiz de Erechun F, Mirada A, Rossi AB. An open-label, multicenter study of the combination of amorolfine nail lacquer and oral itraconazole compared with oral itraconazole alone in the treatment of severe toenail onychomycosis. Curr Ther Res 2002; 63: 366-379.
56. Olafsson J, Sigurgeirsson B, Baran R. Combination therapy for onychomycosis. Br J Dermatol 2003; 149 (Suppl. 65): 15-18.
57. Heikkila H, Stubb S. Long-term results of patients with onychomycosis treated with itraconazole. Acta Derm Venereol 1997; 77: 70-71.
58. Sigurgeirsson B, Olafsson J, Steinsson J. Long-term effectiveness of treatment with terbinafine vs itraconazole in onychomycosis. Arch Dermatol 2002; 138: 353-357.